N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
申请人:Lewis and Clark Pharmaceuticals, Inc.
公开号:US09067963B2
公开(公告)日:2015-06-30
The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5′-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
[EN] N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS<br/>[FR] UTILISATION DE N-ALKYL-2-(DISUBSTITUÉ)ALKYNYLADÉNOSINE-5-URONAMIDES COMME AGONISTES DU RÉCEPTEUR A2A
申请人:LEWIS AND CLARK PHARMACEUTICALS INC
公开号:WO2014022577A1
公开(公告)日:2014-02-06
The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5'-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS
申请人:Lewis and Clark Pharmaceuticals, LLC
公开号:US20140037538A1
公开(公告)日:2014-02-06
The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5′-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A
2A
adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.